CG Oncology, Inc. 8-K

What Happened
CG Oncology, Inc. announced its earnings and financial results for the quarter and fiscal year ended December 31, 2025 by issuing a press release on February 27, 2026. The company filed a Current Report on Form 8‑K (Item 2.02) to disclose the results; the press release is attached as Exhibit 99.1 to the filing. The filing notes, pursuant to Form 8‑K instructions, that the press release is furnished and not “filed” for purposes of Section 18 of the Exchange Act.

Key Details

• Press release date: February 27, 2026.
• Reporting periods covered: quarter and year ended December 31, 2025 (Q4 2025 and FY2025).
• Disclosure filed under Item 2.02 (Results of Operations and Financial Condition); press release attached as Exhibit 99.1.
• The Form 8‑K states the furnished information is not subject to Section 18 liability (General Instruction B.2).

Why It Matters
This 8‑K communicates CG Oncology’s latest earnings/quarterly results and revenue-related disclosures for investors and analysts. The press release will contain the specific financial figures (revenue, net income/loss, cash position, and any commentary or guidance) that investors use to assess the company’s performance and near‑term prospects. Retail investors should read the attached press release and any subsequent filings (e.g., 10‑K or 10‑Q) for the full financial details before making investment decisions.